Skip to main content

Eddie Pradas Gracia

Institutions of which they are part

Research technician
Neurodegenerative Diseases
Vall Hebron Institut de Recerca

Eddie Pradas Gracia

Institutions of which they are part

Research technician
Neurodegenerative Diseases
Vall Hebron Institut de Recerca

Projects

Malalties neurodegeneratives

IP: Miquel Vila Bover
Collaborators: Jorge Hernández Vara, Joan Compte Barrón, Marta Martínez Vicente, Jordi Bove Badell, Eddie Pradas Gracia, Maria Camprodon Gomez, Marina Lorente Picón, Laura Castillo Ribelles, Oriol de Fabregues-Boixar Nebot, Javier Hoyo Pérez, Ariadna Laguna Tuset, Thais Cuadros Arasa, Jordi Riera Heredia, David Ramos Vicente, Marta Montpeyó Garcia-Moreno, Helena Xicoy Cortada, Malalties neurodegeneratives , Marta González Sepúlveda, Joana Margalida Cladera Sastre, Annabelle Parent, Daniela Samaniego Toro, Daniela Samaniego Toro
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 40000
Reference: 2021 SGR 00784
Duration: 01/01/2022 - 30/06/2025

New nanotechnological therapy for Parkinson's disease: nose-to-brain delivery of GBA-polymer nanoconjugates (NANOGBAtoBRAIN)

IP: Marta Martínez Vicente
Collaborators: José Antonio Arranz Amo, Eddie Pradas Gracia, Laura Castillo Ribelles, Clara Carnicer Cáceres, David Moreno Martinez, Jordi Riera Heredia, Marta Montpeyó Garcia-Moreno, Pablo Castillo Sánchez
Funding agency: Fundació "La Caixa"
Funding: 249950
Reference: HR22-00602
Duration: 01/11/2022 - 31/10/2025

The Vall d’Hebron Iniciative for Parkinson associated to GBA (VHIP-GBA): from biospecimen collection to translational studies and therapies.

IP: Marta Martínez Vicente
Collaborators: José Antonio Arranz Amo, Jorge Hernández Vara, Eddie Pradas Gracia, Guillem Pintos Morell, Clara Carnicer Cáceres, Carles Lorenzo Bosquet, David Moreno Martinez, Jordi Riera Heredia, Marta Montpeyó Garcia-Moreno, Daniela Samaniego Toro, Laura Castillo Ribelles, Daniela Samaniego Toro
Funding agency: Instituto de Salud Carlos III
Funding: 245932.5
Reference: PI20/00728
Duration: 01/01/2021 - 30/06/2025

Desarrollo de una nueva terapia de reemplazo enzimático basada en nanotecnología para la enfermedad de Parkinson: restablecimiento de la actividad glucocerebrosidasa lisosomal mediante nanoconjugación enzima-polímero de GBA (NANO-ERT).

IP: Marta Martínez Vicente
Collaborators: Eddie Pradas Gracia, David Moreno Martinez, Jordi Riera Heredia, Marta Montpeyó Garcia-Moreno, José Antonio Arranz Amo, Maria Camprodon Gomez, Laura Castillo Ribelles, Clara Carnicer Cáceres
Funding agency: Fundación Banco Bilbao Vizcaya Argentaria
Funding: 124047.74
Reference: BBVA/INVESTIGACIO/MARTINEZ
Duration: 01/05/2020 - 30/07/2023

Related news

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Vall d'Hebron has participated in a phase III clinical trial which confirmed the efficacy and safety of subcutaneous infusion of levodopa therapy.

This initiative is part of a pioneering study that seeks to assess how the relationship between different age groups can influence the quality of life and mental health of patients.

Related professionals

Sarai Garriga Edo

Sarai Garriga Edo

Predoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more
Maria José Santos Bornez

Maria José Santos Bornez

Research technician
Rheumatology
Read more
Amparo García Burillo

Amparo García Burillo

Molecular Medical Imaging
Read more
Cynthia Larissa Gill Mairhofer

Cynthia Larissa Gill Mairhofer

Predoctoral researcher
Infectious Diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.